Another strong quarter for Baxter's specialties
This article was originally published in Clinica
Executive Summary
Baxter's third-quarter sales grew 6% to $2,456 million due to another quarter with strong 15% growth in the medical specialties division. With net income up 9%, "Baxter is on track to reach its financial goals for 1995, including earnings growth in the high single digits and operational cash flow of $500 million," says CEO Vernon Loucks.
You may also be interested in...
Clinuvel’s Phototoxicity Drug Scenesse Approved In Third Market
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
A Biopharma A-List Lineup Aims To Tackle Complex Manufacturing At Resilience
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: